Applications of nanoparticles for brain cancer imaging and therapy

Journal of Biomedical Nanotechnology

Volumn 10, Issue 9, 2014, Pages 1713-1731

  Zhang, Liang ^a   Zhao, Dawen ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Blood brain barrier (BBB); Brain metastasis; Drug delivery; Glioma; Molecular imaging; Nanoparticles

Indexed keywords

BLOOD; DRUG DELIVERY; MOLECULAR IMAGING; NANOPARTICLES; PATHOLOGY; TUMORS;

BLOOD-BRAIN BARRIER; BRAIN METASTASIS; CENTRAL NERVOUS SYSTEMS; CRITICAL CHALLENGES; EPIGENETIC ALTERATIONS; GLIOBLASTOMA MULTIFORME; GLIOMA; NANOPARTICLE SYSTEMS;

BRAIN;

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CELL PENETRATING PEPTIDE; NANOCARRIER; NANOPARTICLE; MOLECULAR PROBE;

BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN METASTASIS; CANCER SURVIVAL; CANCER THERAPY; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEM; EPIGENETICS; GLIOBLASTOMA; HUMAN; LETHALITY; MULTIMODAL IMAGING; NANOPROBE; NANOTECHNOLOGY; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; BRAIN NEOPLASMS; DIAGNOSTIC USE; MOLECULAR PROBE; PATHOLOGY; PERMEABILITY; THERAPEUTIC USE;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; HUMANS; MOLECULAR PROBES; NANOPARTICLES; NEUROIMAGING; PERMEABILITY;

EID: 84904891918     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1896     Document Type: Review

References (208)

1. I. T. Gavrilovic and J. B. Posner, Brain metastases: Epidemiology and pathophysiology. J. Neurooncol. 75, 5 (2005).
2. J. S. Barnholtz-Sloan, A. E. Sloan, F. G. Davis, F. D. Vigneau, P. Lai, and R. E. Sawaya, Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J. Clin. Oncol. 22, 2865 (2004).
3. L. J. Schouten, J. Rutten, H. A. Huveneers, and A. Twijnstra, Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94, 2698 (2002).
4. A. Subramanian, A. Harris, K. Piggott, C. Shieff, and R. Bradford, Metastasis to and from the central nervous system - the 'relatively protected site.' Lancet. Oncol. 3, 498 (2002).
5. D. J. Begley, Delivery of therapeutic agents to the central nervous system: The problems and the possibilities. Pharmacol. Ther. 104, 29 (2004).
6. N. D. Doolittle, L. E. Abrey, W. A. Bleyer, S. Brem, T. P. Davis, P. Dore-Duffy, L. R. Drewes, W. A. Hall, J. M. Hoffman, A. Korfel, R. Martuza, L. L. Muldoon, D. Peereboom, D. R. Peterson, S. D. Rabkin, Q. Smith, G. H. Stevens, and E. A. Neuwelt, New frontiers in translational research in neuro-oncology and the blood-brain barrier: Report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin. Cancer. Res. 11, 421 (2005).
7. L. Gaspar, C. Scott, M. Rotman, S. Asbell, T. Phillips, T. Wasserman, W. G. McKenna, and R. Byhardt, Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37, 745 (1997).
8. J. Lutterbach, S. Bartelt, and C. Ostertag, Long-term survival in patients with brain metastases. J. Cancer. Res. Clin. Oncol. 128, 417 (2002).
9. N. Howlader, A. M. Noone, M. Krapcho, J. Garshell, N. Neyman, S. F. Altekruse, C. L. Kosary, M. Yu, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, D. R. Lewis, H. S. Chen, E. J. Feuer, and K. A. Cronin (eds.), SEER Cancer Statistics Review, 1975-2010 National Cancer Institute. Bethesda, MD (2013),
10. P. Y. Wen and S. Kesari, Malignant gliomas in adults. N. Engl. J. Med. 359, 492 (2008).
11. R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross, E. Eisenhauer, and R. O. Mirimanoff, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987 (2005).
12. F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, L. Chin, R. A. DePinho, and W. K. Cavenee, Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes. Dev. 21, 2683 (2007).
13. R. A. Kroll and E. A. Neuwelt, Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery 42, 1083 (1998).
14. R. J. Gilbertson and J. N. Rich, Making a tumour's bed: Glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer 7, 733 (2007).
15. R. K. Jain, E. di Tomaso, D. G. Duda, J. S. Loeffler, A. G. Sorensen, and T. T. Batchelor, Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8, 610 (2007).
16. S. Agarwal, R. Sane, R. Oberoi, J. R. Ohlfest, and W. F. Elmquist, Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert. Rev. Mol. Med. 13, e17 (2011).
17. Y. Boucher, H. Salehi, B. Witwer, G. R. t. Harsh, and R. K. Jain, Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br. J. Cancer 75, 829 (1997).
18. V. P. Torchilin, Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145 (2005).
19. F. Pastorino, C. Brignole, D. Marimpietri, P. Sapra, E. H. Moase, T. M. Allen, and M. Ponzoni, Doxorubicin-loaded Fab' fragments of anti- disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 63, 86 (2003).
20. A. L. Klibanov, K. Maruyama, V. P. Torchilin, and L. Huang, Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268, 235 (1990).
21. A. A. Gabizon, Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19, 424 (2001).
22. Y. Cheng, R. A. Morshed, B. Auffinger, A. L. Tobias, and M. S. Lesniak, Multifunctional nanoparticles for brain tumor imaging and therapy. Adv. Drug Deliv. Rev. 66, 42 (2014).
23. J. D. Meyers, T. Doane, C. Burda, and J. P. Basilion, Nanoparticles for imaging and treating brain cancer. Nanomedicine (Lond) 8, 123 (2013).
24. S. Wohlfart, S. Gelperina, and J. Kreuter, Transport of drugs across the blood-brain barrier by nanoparticles. J. Control Release 161, 264 (2012).
25. L. S. Del Burgo, R. M. Hernandez, G. Orive, and J. L. Pedraz, Nanotherapeutic approaches for brain cancer management. Nanomedicine, Epub ahead of print (2013).
26. R. Gabathuler, Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37, 48 (2010).
27. B. Kateb, K. Chiu, K. L. Black, V. Yamamoto, B. Khalsa, J. Y. Ljubimova, H. Ding, R. Patil, J. A. Portilla-Arias, M. Modo, D. F. Moore, K. Farahani, M. S. Okun, N. Prakash, J. Neman, D. Ahdoot, W. Grundfest, S. Nikzad, and J. D. Heiss, Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: What should be the policy? Neuroimage 54, S106 (2011).
28. Y. Chen and L. Liu, Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 64, 640 (2012).
29. S. Ohtsuki and T. Terasaki, Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm. Res. 24, 1745 (2007).
30. W. M. Pardridge, CNS drug design based on principles of blood-brain barrier transport. J. Neurochem. 70, 1781 (1998).
31. W. M. Pardridge, Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem. Res. 23, 635 (1998).
32. B. T. Hawkins and T. P. Davis, The blood-brain barrier/neurovascular unit in health and disease. Pharmacol. Rev. 57, 173 (2005).
33. K. M. Mahar Doan, J. E. Humphreys, L. O. Webster, S. A. Wring, L. J. Shampine, C. J. Serabjit-Singh, K. K. Adkison, and J. W. Polli, Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 303, 1029 (2002).
34. H. Pajouhesh and G. R. Lenz, Medicinal chemical properties of successful central nervous system drugs. NeuroRx. 2, 541 (2005).
35. B. T. Hawkins and R. D. Egleton, Fluorescence imaging of blood-brain barrier disruption. J. Neurosci. Methods 151, 262 (2006).
36. I. J. Fidler, S. Yano, R. D. Zhang, T. Fujimaki, and C. D. Bucana, The seed and soil hypothesis: Vascularisation and brain metastases. Lancet. Oncol. 3, 53 (2002).
37. R. L. Fine, J. Chen, C. Balmaceda, J. N. Bruce, M. Huang, M. Desai, M. B. Sisti, G. M. McKhann, R. R. Goodman, J. S. Bertino, Jr., A. N. Nafziger, and M. R. Fetell, Randomized study of paclitaxel and tamoxifen deposition into human brain tumors: Implications for the treatment of metastatic brain tumors. Clin. Cancer Res. 12, 5770 (2006).
38. M. W. Pitz, A. Desai, S. A. Grossman, and J. O. Blakeley, Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J. Neurooncol. 104, 629 (2011).
39. S. Fattori, F. Becherini, M. Cianfriglia, G. Parenti, A. Romanini and M. Castagna, Human brain tumors: Multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Virchows. Arch. 451, 81 (2007).
40. L. Doyle and D. D. Ross, Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22, 7340 (2003).
41. A. Regina, M. Demeule, A. Laplante, J. Jodoin, C. Dagenais, F. Berthelet, A. Moghrabi, and R. Beliveau, Multidrug resistance in brain tumors: Roles of the blood-brain barrier. Cancer Metastasis Rev. 20, 13 (2001).
42. M. Demeule, D. Shedid, E. Beaulieu, R. F. Del Maestro, A. Moghrabi, P. B. Ghosn, R. Moumdjian, F. Berthelet, and R. Beliveau, Expression of multidrug-resistance P-glycoprotein (MDR1) in human brain tumors. Int. J. Cancer 93, 62 (2001).
43. R. D. Zhang, J. E. Price, T. Fujimaki, C. D. Bucana, and I. J. Fidler, Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am. J. Pathol. 141, 1115 (1992).
44. P. R. Lockman, R. K. Mittapalli, K. S. Taskar, V. Rudraraju, B. Gril, K. A. Bohn, C. E. Adkins, A. Roberts, H. R. Thorsheim, J. A. Gaasch, S. Huang, D. Palmieri, P. S. Steeg, and Q. R. Smith, Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin. Cancer Res. 16, 5664 (2010).
45. H. Zhou, M. Chen, and D. Zhao, Longitudinal MRI evaluation of intracranial development and vascular characteristics of breast cancer brain metastases in a mouse model. PLoS One 8 e62238 (2013).
46. D. B. Percy, E. J. Ribot, Y. Chen, C. McFadden, C. Simedrea, P. S. Steeg, A. F. Chambers, and P. J. Foster, In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: A complementary magnetic resonance imaging approach. Invest. Radiol. 46, 718 (2011).
47. P. S. Tofts, Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J. Magn. Reson. Imaging 7, 91 (1997).
48. J. R. Ewing, S. L. Brown, M. Lu, S. Panda, G. Ding, R. A. Knight, Y. Cao, Q. Jiang, T. N. Nagaraja, J. L. Churchman, and J. D. Fenstermacher, Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J. Cereb. Blood Flow Metab. 26, 310 (2006).
49. D. Palmieri, P. R. Lockman, F. C. Thomas, E. Hua, J. Herring, E. Hargrave, M. Johnson, N. Flores, Y. Qian, E. Vega-Valle, K. S. Taskar, V. Rudraraju, R. K. Mittapalli, J. A. Gaasch, K. A. Bohn, H. R. Thorsheim, D. J. Liewehr, S. Davis, J. F. Reilly, R. Walker, J. L. Bronder, L. Feigenbaum, S. M. Steinberg, K. Camphausen, P. S. Meltzer, V. M. Richon, Q. R. Smith, and P. S. Steeg, Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin. Cancer Res. 15, 6148 (2009).
50. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751 (2007).
51. C. K. Anders, B. Adamo, O. Karginova, A. M. Deal, S. Rawal, D. Darr, A. Schorzman, C. Santos, R. Bash, T. Kafri, L. Carey, C. R. Miller, C. M. Perou, N. Sharpless, and W. C. Zamboni, Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. PLoS One 8, e61359 (2013).
52. M. I. Koukourakis, S. Koukouraki, I. Fezoulidis, N. Kelekis, G. Kyrias, S. Archimandritis, and N. Karkavitsas, High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours. Br. J. Cancer 83, 1281 (2000).
53. T. L. Andresen, S. S. Jensen, and K. Jorgensen, Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Prog. Lipid Res. 44, 68 (2005).
54. A. Kheirolomoom, C. Y. Lai, S. M. Tam, L. M. Mahakian, E. S. Ingham, K. D. Watson, and K. W. Ferrara, Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia. J. Control. Release 172, 266 (2013).
55. M. C. Chamberlain, Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: A retrospective case series. J. Neurooncol. 109, 143 (2012).
56. A. Orthmann, R. Zeisig, R. Suss, D. Lorenz, M. Lemm, and I. Fichtner, Treatment of experimental brain metastasis with MTO-liposomes: Impact of fluidity and LRP-targeting on the therapeutic result. Pharm. Res. 29, 1949 (2012).
57. J.-Q. Gao, Q. Lv, L.-M. Li, X.-J. Tang, F.-Z. Li, Y.-L. Hu, and M. Han, Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials 34, 5628 (2013).
58. P. M. Costa, A. L. Cardoso, L. S. Mendonca, A. Serani, C. Custodia, M. Conceicao, S. Simoes, J. N. Moreira, L. Pereira de Almeida, and M. C. Pedroso de Lima, Tumor-targeted chlorotoxincoupled nanoparticles for nucleic acid delivery to glioblastoma cells: A promising system for glioblastoma treatment. Mol. Ther. Nucleic. Acids 2, e100 (2013).
59. J. M. Munson, L. Fried, S. A. Rowson, M. Y. Bonner, L. Karumbaiah, B. Diaz, S. A. Courtneidge, U. G. Knaus, D. J. Brat, J. L. Arbiser, and R. V. Bellamkonda, Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci. Transl. Med. 4, 127ra36 (2012).
60. A. B. Madhankumar, B. Slagle-Webb, X. Wang, Q. X. Yang, D. A. Antonetti, P. A. Miller, J. M. Sheehan, and J. R. Connor, Efficacy of interleukin-13 receptor-targeted liposomal doxorubicin in the intracranial brain tumor model. Mol. Cancer Ther. 8, 648 (2009).
61. L. Guo, L. Fan, Z. Pang, J. Ren, Y. Ren, J. Li, J. Chen, Z. Wen and X. Jiang, TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J. Control Release 154, 93 (2011).
62. L. P. Serwer, C. O. Noble, K. Michaud, D. C. Drummond, D. B. Kirpotin, T. Ozawa, M. D. Prados, J. W. Park, and C. D. James, Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts. Neuro. Oncol. 13, 1288 (2011).
63. R. Zhou, R. V. Mazurchuk, J. H. Tamburlin, J. M. Harrold, D. E. Mager, and R. M. Straubinger, Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model. J. Pharmacol. Exp. Ther. 332, 479 (2010).
64. T. Kato, A. Natsume, H. Toda, H. Iwamizu, T. Sugita, R. Hachisu, R. Watanabe, K. Yuki, K. Motomura, K. Bankiewicz, and T. Wakabayashi, Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther. 17, 1363 (2010).
65. T. Skjørringe, T. Gjetting, and T. G. Jensen, A modified protocol for efficient DNA encapsulation into pegylated immunoliposomes (PILs). J. Control. Release 139, 140 (2009).
66. B. Feng, K. Tomizawa, H. Michiue, S.-I. Miyatake, X.-J. Han, A. Fujimura, M. Seno, M. Kirihata, and H. Matsui, Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials 30, 1746 (2009).
67. Y. T. Ko, R. Bhattacharya, and U. Bickel, Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting. J. Control. Release 133, 230 (2009).
68. S. Zhao, X. Zhang, J. Zhang, J. Zhang, H. Zou, Y. Liu, X. Dong, and X. Sun, Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains. J. Chemother. 20, 253 (2008).
69. T. Yin, P. Wang, J. Li, R. Zheng, B. Zheng, D. Cheng, R. Li, J. Lai, and X. Shuai, Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas. Biomaterials 34, 4532 (2013).
70. Y. Miura, T. Takenaka, K. Toh, S. Wu, H. Nishihara, M. R. Kano, Y. Ino, T. Nomoto, Y. Matsumoto, H. Koyama, H. Cabral, N. Nishiyama, and K. Kataoka, Cyclic RGD-Linked Polymeric Micelles for Targeted Delivery of Platinum Anticancer Drugs to Glioblastoma through the Blood-Brain Tumor Barrier. ACS. Nano 7, 8583 (2013).
71. J.-I. Kuroda, J.-I. Kuratsu, M. Yasunaga, Y. Koga, Y. Saito, and Y. Matsumura, Potent antitumor effect of SN-38-incorporating polymeric micelle, NK012, against malignant glioma. Int. J. Cancer 124, 2505 (2009).
72. T. Inoue, Y. Yamashita, M. Nishihara, S. Sugiyama, Y. Sonoda, T. Kumabe, M. Yokoyama, and T. Tominaga, Therapeutic efficacy of a polymeric micellar doxorubicin infused by convectionenhanced delivery against intracranial 9L brain tumor models. Neuro. Oncol. 11, 151 (2009).
73. Z. Zhang, Q. Sun, J. Zhong, Q. Yang, H. Li, D. Cheng, B. Liang, and X. Shuai, Magnetic resonance imaging-visible and pH-sensitive polymeric micelles for tumor targeted drug delivery. J. Biomed. Nanotechnol. 10, 216 (2014).
74. Y. Li, H. He, X. Jia, W.-L. Lu, J. Lou, and Y. Wei, A dualtargeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 33, 3899 (2012).
75. H. M. Teow, Z. Zhou, M. Najlah, S. R. Yusof, N. J. Abbott, and A. D'Emanuele, Delivery of paclitaxel across cellular barriers using a dendrimer-based nanocarrier. Int. J. Pharm. 441, 701 (2013).
76. H. Yan, J. Wang, P. Yi, H. Lei, C. Zhan, C. Xie, L. Feng, J. Qian, J. Zhu, W. Lu, and C. Li, Imaging brain tumor by dendrimerbased optical/paramagnetic nanoprobe across the blood-brain barrier. Chem. Commun. 47, 8130 (2011).
77. Y. Ren, C.-S. Kang, X.-B. Yuan, X. Zhou, P. Xu, L. Han, G. X. Wang, Z. Jia, Y. Zhong, S. Yu, J. Sheng, and P.-Y. Pu, Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J. Biomater. Sci. Polym. Ed. 21, 303 (2010).
78. T. J. Abel, T. Ryken, M. S. Lesniak, and P. Gabikian, Gliadel for brain metastasis. Surg Neurol. Int. 4, S289 (2013).
79. R. K. Mittapalli, X. Liu, C. E. Adkins, M. I. Nounou, K. A. Bohn, T. B. Terrell, H. S. Qhattal, W. J. Geldenhuys, D. Palmieri, P. S. Steeg, Q. R. Smith, and P. R. Lockman, Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model. Mol. Cancer Ther. 12, 2389 (2013).
80. G. R. Reddy, M. S. Bhojani, P. McConville, J. Moody, B. A. Moffat, D. E. Hall, G. Kim, Y. E. Koo, M. J. Woolliscroft, J. V. Sugai, T. D. Johnson, M. A. Philbert, R. Kopelman, A. Rehemtulla, and B. D. Ross, Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin. Cancer Res. 12, 6677 (2006).
81. X. Liu, G. Li, Z. Su, Z. Jiang, L. Chen, J. Wang, S. Yu, and Z. Liu, Poly (amido amine) is an ideal carrier of miR-7 for enhancing gene silencing effects on the EGFR pathway in U251 glioma cells. Oncol. Rep. 29, 1387 (2013).
82. X. Jiang, X. Sha, H. Xin, X. Xu, J. Gu, W. Xia, S. Chen, Y. Xie, L. Chen, Y. Chen, and X. Fang, Integrin-facilitated transcytosis for enhanced penetration of advanced gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating paclitaxel. Biomaterials 34, 2969 (2013).
83. C.-H. Fan, C.-Y. Ting, H.-J. Lin, C.-H. Wang, H.-L. Liu, T.-C. Yen and C.-K. Yeh, SPIO-conjugated, doxorubicin-loaded microbubbles for concurrent MRI and focused-ultrasound enhanced brain-tumor drug delivery. Biomaterials 34, 3706 (2013).
84. Y. Ling, K. Wei, F. Zou, and S. Zhong, Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. Int. J. Pharm. 430, 266 (2012).
85. C. H. Wang, S. T. Kang, and C. K. Yeh, Superparamagnetic iron oxide and drug complex-embedded acoustic droplets for ultrasound targeted theranosis. Biomaterials 34, 1852 (2013).
86. J. Zhou, T. R. Patel, R. W. Sirianni, G. Strohbehn, M. Q. Zheng, N. Duong, T. Schafbauer, A. J. Huttner, Y. Huang, R. E. Carson, Y. Zhang, D. J. Sullivan, Jr., J. M. Piepmeier, and W. M. Saltzman, Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc. Natl. Acad. Sci. USA 110, 11751 (2013).
87. R. H. Bobo, D. W. Laske, A. Akbasak, P. F. Morrison, R. L. Dedrick and E. H. Oldfield, Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. USA 91, 2076 (1994).
88. C. G. Hadjipanayis, R. Machaidze, M. Kaluzova, L. Wang, A. J. Schuette, H. Chen, X. Wu, and H. Mao, EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res. 70, 6303 (2010).
89. T. Siegal, R. Rubinstein, F. Bokstein, A. Schwartz, A. Lossos, E. Shalom, R. Chisin, and J. M. Gomori, In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J. Neurosurg. 92, 599 (2000).
90. R. Chopra, N. Vykhodtseva, and K. Hynynen, Influence of exposure time and pressure amplitude on blood-brain-barrier opening using transcranial ultrasound exposures. ACS Chem. Neurosci. 1, 391 (2010).
91. L. H. Treat, N. McDannold, N. Vykhodtseva, Y. Zhang, K. Tam, and K. Hynynen, Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int. J. Cancer 121, 901 (2007).
92. L. H. Treat, N. McDannold, Y. Zhang, N. Vykhodtseva, and K. Hynynen, Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. Ultrasound Med. Biol. 38, 1716 (2012).
93. E. J. Park, Y. Z. Zhang, N. Vykhodtseva, and N. McDannold, Ultrasound-mediated blood-brain/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model. J. Control. Release 163, 277 (2012).
94. F.-Y. Yang, T.-T. Wong, M.-C. Teng, R.-S. Liu, M. Lu, H.-F. Liang and M.-C. Wei, Focused ultrasound and interleukin-4 receptortargeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme. J. Control. Release 160, 652 (2012).
95. W. M. Pardridge, Blood-brain barrier drug targeting: The future of brain drug development. Mol. Interv. 3, 90 (2003).
96. J. Hu, J. Y. Ljubimova, S. Inoue, B. Konda, R. Patil, H. Ding, A. Espinoza, K. A. Wawrowsky, C. Patil, A. V. Ljubimov, and K. L. Black, Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS One. 5, e10108 (2010).
97. J. Chang, A. Paillard, C. Passirani, M. Morille, J. P. Benoit, D. Betbeder, and E. Garcion, Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm. Res. 29, 1495 (2011).
98. S. Miyata, S. Kawabata, R. Hiramatsu, A. Doi, N. Ikeda, T. Yamashita, T. Kuroiwa, S. Kasaoka, K. Maruyama, and S. Miyatake, Computed tomography imaging of transferrin targeting liposomes encapsulating both boron and iodine contrast agents by convection-enhanced delivery to F98 rat glioma for boron neutron capture therapy. Neurosurgery 68, 1380 (2011).
99. P. Zhang, L. Hu, Q. Yin, L. Feng, and Y. Li, Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy. Mol. Pharm. 9, 1590 (2012).
100. F. C. Thomas, K. Taskar, V. Rudraraju, S. Goda, H. R. Thorsheim, J. A. Gaasch, R. K. Mittapalli, D. Palmieri, P. S. Steeg, P. R. Lockman, and Q. R. Smith, Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 26, 2486 (2009).
101. M. Demeule, J. C. Currie, Y. Bertrand, C. Che, T. Nguyen, A. Regina, R. Gabathuler, J. P. Castaigne, and R. Beliveau, Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J. Neurochem. 106, 1534 (2008).
102. J. Ren, S. Shen, D. Wang, Z. Xi, L. Guo, Z. Pang, Y. Qian, X. Sun and X. Jiang, The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 33, 3324 (2012).
103. F. Heitz, M. C. Morris, and G. Divita, Twenty years of cell-penetrating peptides: From molecular mechanisms to therapeutics. Br. J. Pharmacol. 157, 195 (2009).
104. S. B. Fonseca, M. P. Pereira, and S. O. Kelley, Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv. Drug Deliv. Rev. 61, 953 (2009).
105. H. Barash, R. G. E, Y. Edrei, E. Ella, A. Israel, I. Cohen, N. Corchia, T. Ben-Moshe, O. Pappo, E. Pikarsky, D. Goldenberg, Y. Shiloh, E. Galun, and R. Abramovitch, Accelerated carcinogenesis following liver regeneration is associated with chronic inflammation-induced double-strand DNA breaks. Proc. Natl. Acad. Sci. U. S. A. 107, 2207 (2010).
106. P. Kumar, H. Wu, J. L. McBride, K. E. Jung, M. H. Kim, B. L. Davidson, S. K. Lee, P. Shankar, and N. Manjunath, Transvascular delivery of small interfering RNA to the central nervous system. Nature 448, 39 (2007).
107. M. Mazel, P. Clair, C. Rousselle, P. Vidal, J. M. Scherrmann, D. Mathieu, and J. Temsamani, Doxorubicin-peptide conjugates overcome multidrug resistance. Anticancer Drugs 12, 107 (2001).
108. Y. Qin, H. Chen, W. Yuan, R. Kuai, Q. Zhang, F. Xie, L. Zhang, Z. Zhang, J. Liu, and Q. He, Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int. J. Pharm. 419, 85 (2011).
109. L. Han, A. Zhang, H. Wang, P. Pu, X. Jiang, C. Kang, and J. Chang, Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum. Gene Ther. 21, 417 (2009).
110. J. D. Hood and D. A. Cheresh, Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2, 91 (2002).
111. J. P. Xiong, T. Stehle, R. Zhang, A. Joachimiak, M. Frech, S. L. Goodman, and M. A. Arnaout, Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand. Science 296, 151 (2002).
112. W. Cai and X. Chen, Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med. Chem. 6, 407 (2006).
113. C. Zhan, Q. Meng, Q. Li, L. Feng, J. Zhu, and W. Lu, Cyclic RGDpolyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene delivery. Chem. Asian, J 7, 91 (2012).
114. S. Ran, A. Downes, and P. E. Thorpe, Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 62, 6132 (2002).
115. S. Ran and P. E. Thorpe, Phosphatidylserine is a marker of tumor vasculature and a potential target for cancer imaging and therapy. Int. J. Radiat. Oncol. Biol. Phys. 54, 1479 (2002).
116. X. Huang, M. Bennett, and P. E. Thorpe, A monoclonal antibody that binds anionic phospholipids on tumor blood vessels enhances the antitumor effect of docetaxel on human breast tumors in mice. Cancer Res. 65, 4408 (2005).
117. A. K. Hammill, J. W. Uhr, and R. H. Scheuermann, Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp. Cell Res. 251, 16 (1999).
118. B. Mirnikjoo, K. Balasubramanian, and A. J. Schroit, Mobilization of lysosomal calcium regulates the externalization of phosphatidylserine during apoptosis. J. Biol. Chem. 284, 6918 (2009).
119. K. Balasubramanian and A. J. Schroit, Aminophospholipid asymmetry: A matter of life and death. Annu. Rev. Physiol. 65, 701 (2003).
120. J. He, T. A. Luster, and P. E. Thorpe, Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res. 13, 5211 (2007).
121. P. E. Thorpe, Vascular targeting agents as cancer therapeutics. Clin. Cancer Res. 10, 415 (2004).
122. H. Zhou, J. H. Stafford, R. R. Hallac, L. Zhang, G. Huang, R. P. Mason, J. Gao, P. E. Thorpe, and D. Zhao, Phosphatidylserine-targeted molecular imaging of tumor vasculature by MRI. J. Biomed. Nanotechnol. 10, 846 (2014).
123. L. Zhang and D. Zhao, Liposomal encapsulation enhances in vivo near infrared imaging of exposed phosphatidylserine in a mouse glioma model. Molecules 18, 14613 (2013).
124. D. Zhao, J. H. Stafford, H. Zhou, and P. E. Thorpe, Near-infrared Optical Imaging of Exposed Phosphatidylserine in a Mouse Glioma Model. Transl. Oncol. 4, 355 (2011).
125. N. R. Soman, S. L. Baldwin, G. Hu, J. N. Marsh, G. M. Lanza, J. E. Heuser, J. M. Arbeit, S. A. Wickline, and P. H. Schlesinger, Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J. Clin. Invest. 119, 2830 (2009).
126. D. B. Kirpotin, D. C. Drummond, Y. Shao, M. R. Shalaby, K. Hong, U. B. Nielsen, J. D. Marks, C. C. Benz, and J. W. Park, Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66, 6732 (2006).
127. G. Bao and X. R. Bao, Shedding light on the dynamics of endocytosis and viral budding. Proc. Natl. Acad. Sci. U. S. A. 102, 9997 (2005).
128. B. D. Chithrani and W. C. Chan, Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 7, 1542 (2007).
129. L. Y. Chou, K. Ming, and W. C. Chan, Strategies for the intracellular delivery of nanoparticles. Chem. Soc. Rev. 40, 233 (2010).
130. S. Kunjachan, B. Rychlik, G. Storm, F. Kiessling, and T. Lammers, Multidrug resistance: Physiological principles and nanomedical solutions. Adv. Drug Deliv. Rev. 65, 1852 (2013).
131. E. V. Batrakova, S. Li, W. F. Elmquist, D. W. Miller, V. Y. Alakhov, and A. V. Kabanov, Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. Br. J. Cancer 85, 1987 (2001).
132. F. M. Kievit, F. Y. Wang, C. Fang, H. Mok, K. Wang, J. R. Silber, R. G. Ellenbogen, and M. Zhang, Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. J. Control. Release 152, 76 (2011).
133. G. Szakacs, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, and M. M. Gottesman, Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 5, 219 (2006).
134. P. Zhao, H. Wang, H. Gao, C. Li, and Y. Zhang, Reversal of multidrug resistance by magnetic chitosan-Fe(3)O(4) nanoparticle-encapsulated MDR(1) siRNA in glioblastoma cell line. Neurol. Res. 35, 821 (2013).
135. K. J. Hatanpaa, S. Burma, D. Zhao, and A. A. Habib, Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance. Neoplasia 12, 675 (2011).
136. C. Mamot, D. C. Drummond, C. O. Noble, V. Kallab, Z. Guo, K. Hong, D. B. Kirpotin, and J. W. Park, Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 65, 11631 (2005).
137. P. S. Steeg, K. A. Camphausen, and Q. R. Smith, Brain metastases as preventive and therapeutic targets. Nat. Rev. Cancer 11, 352 (2011).
138. S. Huang, J. Li, L. Han, S. Liu, H. Ma, R. Huang, and C. Jiang, Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials 32, 6832 (2011).
139. S. Wagner, F. Rothweiler, M. G. Anhorn, D. Sauer, I. Riemann, E. C. Weiss, A. Katsen-Globa, M. Michaelis, J. Cinatl, Jr, D. Schwartz, J. Kreuter, H. von Briesen, and K. Langer, Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31, 2388 (2010).
140. H. Xin, X. Jiang, J. Gu, X. Sha, L. Chen, K. Law, Y. Chen, X. Wang, Y. Jiang, and X. Fang, Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon- caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32, 4293 (2011).
141. D. Miao, M. Jiang, Z. Liu, G. Gu, Q. Hu, T. Kang, Q. Song, L. Yao, W. Li, X. Gao, M. Sun, and J. Chen, Co-administration of dual-targeting nanoparticles with penetration enhancement peptide for antiglioblastoma therapy. Mol. Pharm. 11, 90 (2013).
142. M. Jin, G. Hao, X. Sun, and W. Chen, Nanoparticle-based positron emission tomography, and single photon emission computed tomography imaging of cancer. Rev. Nanosci. Nanotechnol. 1, 3 (2012).
143. N. Oku, M. Yamashita, Y. Katayama, T. Urakami, K. Hatanaka, K. Shimizu, T. Asai, H. Tsukada, S. Akai, and H. Kanazawa, PET imaging of brain cancer with positron emitter-labeled liposomes. Int. J. Pharm. 403, 170 (2011).
144. Z. Liu, W. Cai, L. He, N. Nakayama, K. Chen, X. Sun, X. Chen, and H. Dai, In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2, 47 (2007).
145. F. Y. Huang, T. W. Lee, C. H. Kao, C. H. Chang, X. Zhang, W. Y. Lee, W. J. Chen, S. C. Wang, and J. M. Lo, Imaging, autoradiography, and biodistribution of (188)Re-labeled PEGylated nanoliposome in orthotopic glioma bearing rat model. Cancer Biother. Radiopharm. 26, 717 (2011).
146. A. R. Hsu, W. Cai, A. Veeravagu, K. A. Mohamedali, K. Chen, S. Kim, H. Vogel, L. C. Hou, V. Tse, M. G. Rosenblum, and X. Chen, Multimodality molecular imaging of glioblastoma growth inhibition with vasculature-targeting fusion toxin VEGF121/rGel. J. Nucl. Med. 48, 445 (2007).
147. X. Lu, C. H. Yan, M. Yuan, Y. Wei, G. Hu, and Y. Kang, In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer Res. 70, 3905 (2010).
148. C. M. McCann, P. Waterman, J. L. Figueiredo, E. Aikawa, R. Weissleder, and J. W. Chen, Combined magnetic resonance and fluorescence imaging of the living mouse brain reveals glioma response to chemotherapy. Neuroimage 45, 360 (2009).
149. H. Zhou, K. Luby-Phelps, B. E. Mickey, A. A. Habib, R. P. Mason and D. Zhao, Dynamic near-infrared optical imaging of 2-deoxyglucose uptake by intracranial glioma of athymic mice. PLoS One 4, e8051 (2009).
150. J. L. Kovar, E. Curtis, S. F. Othman, M. A. Simpson, and D. M. Olive, Characterization of IRDye 800CW chlorotoxin as a targeting agent for brain tumors. Anal. Biochem. 440, 212 (2013).
151. X. He, J. Gao, S. S. Gambhir, and Z. Cheng, Near-infrared fluorescent nanoprobes for cancer molecular imaging: Status and challenges. Trends. Mol. Med. 16, 574 (2010).
152. U. Iqbal, H. Albaghdadi, Y. Luo, M. Arbabi, C. Desvaux, T. Veres, D. Stanimirovic, and A. Abulrob, Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies. Br. J. Cancer 103, 1606 (2010).
153. W. Stummer, U. Pichlmeier, T. Meinel, O. D. Wiestler, F. Zanella and H. J. Reulen, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet. Oncol. 7, 392 (2006).
154. E. M. Sevick-Muraca, R. Sharma, J. C. Rasmussen, M. V. Marshall, J. A. Wendt, H. Q. Pham, E. Bonefas, J. P. Houston, L. Sampath, K. E. Adams, D. K. Blanchard, R. E. Fisher, S. B. Chiang, R. Elledge, and M. E. Mawad, Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: Feasibility study. Radiology 246, 734 (2008).
155. S. Keereweer, J. D. Kerrebijn, P. B. van Driel, B. Xie, E. L. Kaijzel, T. J. Snoeks, I. Que, M. Hutteman, J. R. van der Vorst, J. S. Mieog, A. L. Vahrmeijer, C. J. van de Velde, R. J. B. de Jong, and C. W. Lowik, Optical image-guided surgery-where do we stand? Mol. Imaging Biol. 13, 199 (2011).
156. H. Orbay, J. Bean, Y. Zhang, and W. Cai, Intraoperative targeted optical imaging: A guide towards tumor-free margins in cancer surgery. Curr. Pharm. Biotechnol. 14, 733 (2014).
157. A. L. Vahrmeijer, M. Hutteman, J. R. van der Vorst, C. J. van de Velde, and J. V. Frangioni, Image-guided cancer surgery using near-infrared fluorescence. Nat. Rev. Clin. Oncol. 10, 507 (2013).
158. E. M. Sevick-Muraca, Translation of near-infrared fluorescence imaging technologies: Emerging clinical applications. Annu. Rev. Med. 63, 217 (2012).
159. E. R. Laws, I. F. Parney, W. Huang, F. Anderson, A. M. Morris, A. Asher, K. O. Lillehei, M. Bernstein, H. Brem, A. Sloan, M. S. Berger, and S. Chang, Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the glioma outcomes project. J. Neurosurg. 99, 467 (2003).
160. F. G. Barker, 2nd and S. M. Chang, Improving resection of malignant glioma. Lancet. Oncol. 7, 359 (2006).
161. I. L. Medintz, A. R. Clapp, H. Mattoussi, E. R. Goldman, B. Fisher, and J. M. Mauro, Self-assembled nanoscale biosensors based on quantum dot FRET donors. Nat. Mater. 2, 630 (2003).
162. L. Carlini, H. Chibli, X. Zhang, and J. L. Nadeau, Comparative anti-cancer properties of quantum dots and gold particles conjugated to chemotherapeutic agents. Rev. Nanosci. Nanotechnol. 2, 42 (2013).
163. A. M. Smith, H. Duan, A. M. Mohs, and S. Nie, Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv. Drug Deliv. Rev. 60, 1226 (2008).
164. R. Singh and H. S. Nalwa, Medical applications of nanoparticles in biological imaging, cell labeling, antimicrobial agents, and anticancer nanodrugs. J. Biomed. Nanotechnol. 7, 489 (2011).
165. N. S. Rejinold, T. Baby, S. V. Nair, and R. Jayakumar, Paclitaxel loaded fibrinogen coated CdTe/ZnTe core shell nanoparticles for targeted imaging and drug delivery to breast cancer cells. J. Biomed. Nanotechnol. 9, 1657 (2013).
166. S. P. Singh, Multifunctional magnetic quantum dots for cancer theranostics. J. Biomed. Nanotechnol. 7, 95 (2011).
167. J. Wang, W. H. Yong, Y. Sun, P. T. Vernier, H. P. Koeffler, M. A. Gundersen, and L. Marcu, Receptor-targeted quantum dots: Fluorescent probes for brain tumor diagnosis. J. Biomed. Opt. 12, 044021 (2007).
168. C. Yang, W. Chen, B. G. Bui, and G. Xiang, Recent progress on the liposomes loaded with quantum dots. Rev. Nanosci. Nanotechnol. 1, 257 (2012).
169. J. You, R. Zhang, C. Xiong, M. Zhong, M. Melancon, S. Gupta, A. M. Nick, A. K. Sood, and C. Li, Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res. 72, 4777 (2012).
170. M. P. Melancon, W. Lu, M. Zhong, M. Zhou, G. Liang, A. M. Elliott, J. D. Hazle, J. N. Myers, C. Li, and R. J. Stafford, Targeted multifunctional gold-based nanoshells for magnetic resonance-guided laser ablation of head and neck cancer. Biomaterials 32, 7600 (2011).
171. J. Cheng, Y. J. Gu, S. H. Cheng, and W. T. Wong, Surface functionalized gold nanoparticles for drug delivery. J. Biomed. Nanotechnol. 9, 1362 (2013).
172. T. Gong, M. Olivo, U. S. Dinish, D. Goh, K. V. Kong, and K. T. Yong, Engineering bioconjugated gold nanospheres and gold nanorods as label-free plasmon scattering probes for ultrasensitive multiplex dark-field imaging of cancer cells. J. Biomed. Nanotechnol. 9, 985 (2013).
173. M. F. Kircher, A. de la Zerda, J. V. Jokerst, C. L. Zavaleta, P. J. Kempen, E. Mittra, K. Pitter, R. Huang, C. Campos, F. Habte, R. Sinclair, C. W. Brennan, I. K. Mellinghoff, E. C. Holland, and S. S. Gambhir, A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat. Med. 18, 829 (2012).
174. J. W. Bulte and D. L. Kraitchman, Iron oxide MR contrast agents for molecular and cellular imaging. NMR. Biomed. 17, 484 (2004).
175. D. L. Thorek, A. K. Chen, J. Czupryna, and A. Tsourkas, Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann. Biomed. Eng. 34, 23 (2006).
176. R. Weissleder and M. J. Pittet, Imaging in the era of molecular oncology. Nature 452, 580 (2008).
177. B. Tomanek, U. Iqbal, B. Blasiak, A. Abulrob, H. Albaghdadi, J. R. Matyas, D. Ponjevic, and G. R. Sutherland, Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging. Neuro. Oncol. 14, 53 (2012).
178. F. Zhang, X. Huang, L. Zhu, N. Guo, G. Niu, M. Swierczewska, S. Lee, H. Xu, A. Y. Wang, K. A. Mohamedali, M. G. Rosenblum, G. Lu, and X. Chen, Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 33, 5414 (2012).
179. J. Huang, L. Wang, L. Yang, and H. Mao, High r1 relaxivity Sub-5 nm supersmall iron oxide nanoparticles (sSIO) as T1 weighted MRI contrast agents, World Molecular Imaging Congress, Savannah, GE (2013).
180. O. Veiseh, C. Sun, C. Fang, N. Bhattarai, J. Gunn, F. Kievit, K. Du, B. Pullar, D. Lee, R. G. Ellenbogen, J. Olson, and M. Zhang, Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res. 69, 6200 (2009).
181. H. Y. Lee, Z. Li, K. Chen, A. R. Hsu, C. Xu, J. Xie, S. Sun, and X. Chen, PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med. 49, 1371 (2008).
182. H. Yan, L. Wang, J. Wang, X. Weng, H. Lei, X. Wang, L. Jiang, J. Zhu, W. Lu, X. Wei, and C. Li, Two-order targeted brain tumor imaging by using an optical/paramagnetic nanoprobe across the blood brain barrier. ACS Nano 6, 410 (2012).
183. M. E. Melisko, D. H. Moore, P. K. Sneed, J. De Franco, and H. S. Rugo, Brain metastases in breast cancer: Clinical and pathologic characteristics associated with improvements in survival. J. Neurooncol. 88, 359 (2008).
184. N. U. Lin, J. R. Bellon, and E. P. Winer, CNS metastases in breast cancer. J. Clin. Oncol. 22, 3608 (2004).
185. W. S. Carbonell, O. Ansorge, N. Sibson, and R. Muschel, The vascular basement membrane as "soil" in brain metastasis. PLoS One. 4, e5857 (2009).
186. J. C. Bendell, S. M. Domchek, H. J. Burstein, L. Harris, J. Younger, I. Kuter, C. Bunnell, M. Rue, R. Gelman, and E. Winer, Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97, 2972 (2003).
187. J. W. Welsh, R. Komaki, A. Amini, M. F. Munsell, W. Unger, P. K. Allen, J. Y. Chang, J. S. Wefel, S. L. McGovern, L. L. Garland, S. S. Chen, J. Holt, Z. Liao, P. Brown, E. Sulman, J. V. Heymach, E. S. Kim, and B. Stea, Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J. Clin. Oncol. 31, 895 (2013).
188. H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M. J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B. A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G. J. Riggins, D. D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J. W. Ho, S. Y. Leung, S. T. Yuen, B. L. Weber, H. F. Seigler, T. L. Darrow, H. Paterson, R. Marais, C. J. Marshall, R. Wooster, M. R. Stratton, and P. A. Futreal, Mutations of the BRAF gene in human cancer. Nature 417, 949 (2002).
189. R. K. Mittapalli, S. Vaidhyanathan, A. Z. Dudek, and W. F. Elmquist, Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: Implications for the treatment of melanoma brain metastases. J. Pharmacol. Exp. Ther. 344, 655 (2013).
190. K. T. Flaherty, J. R. Infante, A. Daud, R. Gonzalez, R. F. Kefford, J. Sosman, O. Hamid, L. Schuchter, J. Cebon, N. Ibrahim, R. Kudchadkar, H. A. Burris, 3rd, G. Falchook, A. Algazi, K. Lewis, G. V. Long, I. Puzanov, P. Lebowitz, A. Singh, S. Little, P. Sun, A. Allred, D. Ouellet, K. B. Kim, K. Patel, and J. Weber, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694 (2012).
191. J. W. Polli, J. E. Humphreys, K. A. Harmon, S. Castellino, M. J. O'Mara, K. L. Olson, L. S. John-Williams, K. M. Koch, and C. J. Serabjit-Singh, The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy] phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl] -4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab. Dispos. 36, 695 (2008).
192. K. S. Taskar, V. Rudraraju, R. K. Mittapalli, R. Samala, H. R. Thorsheim, J. Lockman, B. Gril, E. Hua, D. Palmieri, J. W. Polli, S. Castellino, S. D. Rubin, P. R. Lockman, P. S. Steeg, and Q. R. Smith, Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm. Res. 29, 770 (2011).
193. H. Gao, Y. Wang, C. Chen, J. Chen, Y. Wei, S. Cao, and X. Jiang, Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug. Int. J. Pharm. 461, 478 (2014).
194. D. Vergara, C. Bellomo, X. Zhang, V. Vergaro, A. Tinelli, V. Lorusso, R. Rinaldi, Y. M. Lvov, S. Leporatti, and M. Maffia, Lapatinib/Paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomedicine 8, 891 (2012).
195. R. G. Verhaak, K. A. Hoadley, E. Purdom, V. Wang, Y. Qi, M. D. Wilkerson, C. R. Miller, L. Ding, T. Golub, J. P. Mesirov, G. Alexe, M. Lawrence, M. O'Kelly, P. Tamayo, B. A. Weir, S. Gabriel, W. Winckler, S. Gupta, L. Jakkula, H. S. Feiler, J. G. Hodgson, C. D. James, J. N. Sarkaria, C. Brennan, A. Kahn, P. T. Spellman, R. K. Wilson, T. P. Speed, J. W. Gray, M. Meyerson, G. Getz, C. M. Perou, and D. N. Hayes, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98 (2010).
196. H. S. Phillips, S. Kharbanda, R. Chen, W. F. Forrest, R. H. Soriano, T. D. Wu, A. Misra, J. M. Nigro, H. Colman, L. Soroceanu, P. M. Williams, Z. Modrusan, B. G. Feuerstein, and K. Aldape, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157 (2006).
197. P. Kleihues and H. Ohgaki, Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro. Oncol. 1, 44 (1999).
198. J. Chen, Y. Li, T. S. Yu, R. M. McKay, D. K. Burns, S. G. Kernie and L. F. Parada, A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522 (2012).
199. D. Sturm, H. Witt, V. Hovestadt, D. A. Khuong-Quang, D. T. Jones, C. Konermann, E. Pfaff, M. Tonjes, M. Sill, S. Bender, M. Kool, M. Zapatka, N. Becker, M. Zucknick, T. Hielscher, X. Y. Liu, A. M. Fontebasso, M. Ryzhova, S. Albrecht, K. Jacob, M. Wolter, M. Ebinger, M. U. Schuhmann, T. van Meter, M. C. Fruhwald, H. Hauch, A. Pekrun, B. Radlwimmer, T. Niehues, G. von Komorowski, M. Durken, A. E. Kulozik, J. Madden, A. Donson, N. K. Foreman, R. Drissi, M. Fouladi, W. Scheurlen, A. von Deimling, C. Monoranu, W. Roggendorf, C. Herold-Mende, A. Unterberg, C. M. Kramm, J. Felsberg, C. Hartmann, B. Wiestler, W. Wick, T. Milde, O. Witt, A. M. Lindroth, J. Schwartzentruber, D. Faury, A. Fleming, M. Zakrzewska, P. P. Liberski, K. Zakrzewski, P. Hauser, M. Garami, A. Klekner, L. Bognar, S. Morrissy, F. Cavalli, M. D. Taylor, P. van Sluis, J. Koster, R. Versteeg, R. Volckmann, T. Mikkelsen, K. Aldape, G. Reifenberger, V. P. Collins, J. Majewski, A. Korshunov, P. Lichter, C. Plass, N. Jabado, and S. M. Pfister, Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22, 425 (2012).
200. A. B. Heimberger, L. E. Crotty, G. E. Archer, K. R. Hess, C. J. Wikstrand, A. H. Friedman, H. S. Friedman, D. D. Bigner, and J. H. Sampson, Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res. 9, 4247 (2003).
201. J. Mendelsohn and J. Baselga, The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550 (2000).
202. J. T. Huse and E. C. Holland, Targeting brain cancer: Advances in the molecular pathology of malignant glioma and medulloblastoma. Nat. Rev. Cancer 10, 319 (2010).
203. J. N. Rich, D. A. Reardon, T. Peery, J. M. Dowell, J. A. Quinn, K. L. Penne, C. J. Wikstrand, L. B. Van Duyn, J. E. Dancey, R. E. McLendon, J. C. Kao, T. T. Stenzel, B. K. Ahmed Rasheed, S. E. Tourt-Uhlig, J. E. Herndon, 2nd, J. J. Vredenburgh, J. H. Sampson, A. H. Friedman, D. D. Bigner and H. S. Friedman, Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 22, 133 (2004).
204. D. M. Peereboom, D. R. Shepard, M. S. Ahluwalia, C. J. Brewer, N. Agarwal, G. H. Stevens, J. H. Suh, S. A. Toms, M. A. Vogelbaum, R. J. Weil, P. Elson, and G. H. Barnett, Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J. Neurooncol. 98, 93 (2009).
205. E. Galanis, J. C. Buckner, M. J. Maurer, J. I. Kreisberg, K. Ballman, J. Boni, J. M. Peralba, R. B. Jenkins, S. R. Dakhil, R. F. Morton, K. A. Jaeckle, B. W. Scheithauer, J. Dancey, M. Hidalgo, and D. J. Walsh, Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J. Clin. Oncol. 23, 5294 (2005).
206. P. Y. Wen, W. K. Yung, K. R. Lamborn, P. L. Dahia, Y. Wang, B. Peng, L. E. Abrey, J. Raizer, T. F. Cloughesy, K. Fink, M. Gilbert, S. Chang, L. Junck, D. Schiff, F. Lieberman, H. A. Fine, M. Mehta, H. I. Robins, L. M. DeAngelis, M. D. Groves, V. K. Puduvalli, V. Levin, C. Conrad, E. A. Maher, K. Aldape, M. Hayes, L. Letvak, M. J. Egorin, R. Capdeville, R. Kaplan, A. J. Murgo, C. Stiles, and M. D. Prados, Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin. Cancer Res. 12, 4899 (2006).
207. T. F. Cloughesy, P. Y. Wen, H. I. Robins, S. M. Chang, M. D. Groves, K. L. Fink, L. Junck, D. Schiff, L. Abrey, M. R. Gilbert, F. Lieberman, J. Kuhn, L. M. DeAngelis, M. Mehta, J. J. Raizer, W. K. Yung, K. Aldape, J. Wright, K. R. Lamborn, and M. D. Prados, Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium Study. J. Clin. Oncol. 24, 3651 (2006).
208. L. Doherty, D. C. Gigas, S. Kesari, J. Drappatz, R. Kim, J. Zimmerman, L. Ostrowsky, and P. Y. Wen, Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67, 156 (2006).